Biotech Is Well-Positioned To Outperform

Biotech Is Well-Positioned To Outperform


The FDA remains supportive of new drug treatments and we believe the regulatory environment under Trump will continue to be favorable. Health care has been one of the most unpopular areas in the market for more than two years - particularly biotechnology stocks.



from Biotech News